AVTX-002 is a Monoclonal Antibody owned by Avalo Therapeutics, and is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing.

AVTX-002 is a LIGHT ligand inhibitor. The drug candidate regulates the DcR3 levels by inhibiting the LIGHT signals via the lymphotoxin beta receptor and the herpesvirus entry mediator (HVEM) and supress the activities of T cells, NK cells, monocytes or dendric cells through several receptors which are involved in the inflammatory responses.

The revenue for AVTX-002 is expected to reach a total of $1.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the AVTX-002 NPV Report.

AVTX-002 was originated by La Jolla Institute for Immunology and Kyowa Kirin and is currently owned by Avalo Therapeutics.

AVTX-002 Overview

AVTX-002 (AEVI-002, KHK-252067,SAR-252067) is under development for the treatment of severe pediatric onset Crohn’s disease, moderate to severe Crohn's disease, COVID-19 cytokine storm induced acute respiratory distress syndrome, pneumonia, acute lung injury and non-eosinophilic asthma (NEA). It is administered through subcutaneous route. It is a fully human anti-light monoclonal antibody. LIGHT is a tumor necrosis factor (TNF) super-family member that is implicated as a key mediator of inflammation.

It was under development for the treatment of ulcerative colitis.

Avalo Therapeutics Overview

Avalo Therapeutics, formerly Cerecor is a biopharmaceutical company that develops and commercializes novel products in the fields of neurology and pediatrics. The company’s products include prescription medications, prescription devices and dietary supplements. Its pipeline products offer treatment in the areas of neurogenic orthostatic hypotension, parkinsons disease, seizures in epilepsy and deoxyguanosine kinase deficiency. Avalo Therapeutics‘ prescription medications comprise aciphex sprinkle, cefaclor, millipred tablets and dose packs and millipred oral solution, among others. The company also offers dietary supplements such as chewable tablets and drops. Avalo Therapeutics is headquartered in Baltimore, Maryland, the US.

The company reported revenues of (US Dollars) US$5.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 19.4% over FY2020. The operating loss of the company was US$82.1 million in FY2021, compared to an operating loss of US$72.8 million in FY2020. The net loss of the company was US$84.4 million in FY2021, compared to a net loss of US$63.5 million in FY2020. The company reported revenues of US$1 million for the second quarter ended June 2022, a decrease of 11.9% over the previous quarter.

Quick View – AVTX-002

Report Segments
  • Innovator
Drug Name
  • AVTX-002
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Infectious Disease
  • Respiratory
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.